This document summarizes the results of an OncoType DX genomic test for a patient with breast cancer. It provides information on how the test analyzes genes related to proliferation, invasion, estrogen receptor, and other factors. It then outlines the test results and how they correspond to predicted 10-year recurrence risks. Finally, it provides treatment recommendations based on the recurrence score and other clinical risk factors like tumor size and grade.

1. Interpretación del RS
(OncoType DX)

2. Mauricio Lema Medina MD
Clínica de Oncología Astorga / Clínica SOMA
Medellín
Inspirado en: Michael Bierut, 2013, Logo para Mohawk Fine Papers

3. Proliferation
Ki67
STK15
Survivin
CCNB1
MYBL2
Invasion
MMP11
CTSL2
HER2
GRB7
HER2
Estrogen
ER
PGR
BCL2
SCUBE2
Miscelaneous
GSTM1
CD68
BAG1
Reference
ACTB
GAPDH
RPLPO
GUS
TFRC
OncoType DX Expression
RT-PCR

4. N0 N1 N2 N3 M1
T0 Tis IIa IIIa IIIc IV
T1 Ia IIa IIIa IIIc IV
T2 IIa IIb IIIa IIIc IV
T3 IIb IIIa IIIa IIIc IV
T4 IIIb IIIb IIIb IIIc IV
Estrogen receptor or progesterone receptor +
Her2 negative
Unifocal
T size (T1/2): >1 cm and ≤5 cm or >0.5-1 cm, grade 2/3
N0 M0

5. RS 5 = 5% de riesgo de recidiva a 10 años
RS 30 = 20% de riesgo de recidiva a 10 años

6. Mayores de 50
Bajo riesgo
(RS 0-25)
Alto riesgo
(RS 26 o más)

8. ≤ 50 años
Bajo riesgo
(RS 0-15)
Alto riesgo
(RS 21 o más)
Integrarconriesgoclínico

9. Clinical Risk
Grade 1 Grade 2 Grade 3
>0.5 cm - 1 cm High
>1 cm - 2 cm High High
>2 cm High High High

11. ≤50 years-old
21-gene recurrence score assay
(OncoTypeDx)
Luminal A or B (Her2-)
>1-5 cm in size (T1c/2) or >0.5 cm Grade 2 or 3
N0M0
>50 years-old
RSS 0-15 (LR)
Adjuvant hormonal
therapy (no CT)
RSS 16-25
Adjuvant hormonal therapy, CT if
RSS ≥20 or high clinical risk*
RSS >25 (HR)
Adjuvant CT and
hormonal therapy
*High clinical risk is defined as: Tumor >2 cm;
or 1-2 cm, grade 2 or 3; or less ≤1 cm grade 3
RSS: Recurrence score (0-100)
CT: Chemotherapy
EBC: Early-Breast cancer